Cellectar Biosciences (CLRB) vs Vyome (HIND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vyome (HIND) has outperformed Cellectar Biosciences (CLRB) over the past year, losing 67.1% versus a loss of 70.6%. Over five years, CLRB leads with a -99.5% price change compared with -100.0% for HIND. Vyome is the larger company by market cap ($14.3 million vs $14.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | HIND |
|---|---|---|
| Share price | $1.51 | $2.04 |
| Market cap | $14.27M | $14.32M |
| 1-day change | 0.00% | -0.97% |
| YTD return | -48.81% | -40.70% |
| 1-year return | -70.57% | -67.15% |
| 5-year return | -99.45% | -100.00% |
| P/E ratio (TTM) | — | 1.15 |
| EPS (TTM) | $-3.46 | $1.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $6.56 |
| 52-week low | $1.46 | $1.75 |
| Distance from 52-week high | -70.22% | -68.90% |
| Average volume | 61.52K | 13.60K |
| Shares outstanding | 9.45M | 7.02M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CLRB vs HIND FAQ
Which is bigger, Cellectar Biosciences or Vyome?
Vyome (HIND) is larger, with a market capitalization of $14.32M compared with $14.27M for Cellectar Biosciences (CLRB).
Which stock has performed better over the past year, CLRB or HIND?
HIND returned -67.15% over the past 12 months, compared with -70.57% for CLRB (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Vyome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.